title: Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.
abstract: Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.
authors.affiliation: Hospital Universitário Clementino Fraga Filho and Departamento de Histologia e Embriologia, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, RJ, Brasil.
authors.forename: G A P
authors.initials: GA
authors.lastname: Oliveira
authors.forename: E S
authors.initials: ES
authors.lastname: Costa
authors.forename: M S
authors.initials: MS
authors.lastname: Freitas
authors.forename: F F
authors.initials: FF
authors.lastname: Dutra
authors.forename: S F
authors.initials: SF
authors.lastname: Maia
authors.forename: M C
authors.initials: MC
authors.lastname: Guerra
authors.forename: M D
authors.initials: MD
authors.lastname: Tabernero
authors.forename: R
authors.initials: R
authors.lastname: Borojevic
authors.forename: I B
authors.initials: IB
authors.lastname: Otazu
authors.forename: J L
authors.initials: JL
authors.lastname: Silva
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D018365:Neoplasm, Residual; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate